Collaboration Agreement (Tables)

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Collaboration Revenue

Collaboration revenue was as follows:

	Three Months Ended March 31,
	2016		2015
Collaboration revenue:
Related to U.S. XTANDI net sales	$	153,793	$	112,010
Related to ex-U.S. XTANDI net sales		28,704		15,767
Related to upfront and milestone payments		—		1,411
Total	$	182,497	$	129,188

Schedule of Collaboration Revenue Related to U.S. XTANDI Net Sales

Collaboration revenue related to U.S. XTANDI net sales was as follows:

	Three Months Ended March 31,
	2016			2015
U.S. XTANDI net sales (as reported by Astellas)	$	307,586		$	224,020
Shared U.S. development and commercialization costs		(130,583	)		(110,313	)
Pre-tax U.S. profit	$	177,003		$	113,707
Medivation’s share of pre-tax U.S. profit	$	88,501		$	56,853
Reimbursement of Medivation’s share of shared U.S. costs		65,292			55,157
Collaboration revenue related to U.S. XTANDI net sales	$	153,793		$	112,010